Literature DB >> 18794882

The role of PTEN signaling perturbations in cancer and in targeted therapy.

M Keniry1, R Parsons.   

Abstract

The PTEN tumor suppressor was discovered by its homozygous deletion and other mutations in cancer. Since then, PTEN has been shown to be a non-redundant, evolutionarily conserved phosphatase whose function affects diverse cellular progresses such as cell cycle progression, cell proliferation, chemotaxis, apoptosis, aging, muscle contractility, DNA damage response, angiogenesis and cell polarity. In accordance with its ability to influence multiple crucial cellular processes, PTEN has a major role in the pathogenesis of numerous diseases such as diabetes, autism and almost every cancer examined. This review will discuss the diverse ways in which PTEN signaling is modified in cancer, and how these changes correlate with and might possibly affect the action of targeted chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794882     DOI: 10.1038/onc.2008.248

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  145 in total

Review 1.  Role of Forkhead Box Class O proteins in cancer progression and metastasis.

Authors:  Chang Geun Kim; Hyemin Lee; Nehal Gupta; Sharavan Ramachandran; Itishree Kaushik; Sangeeta Srivastava; Sung-Hoon Kim; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2017-08-01       Impact factor: 15.707

Review 2.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Authors:  Inna V Fedorenko; Kim H T Paraiso; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2011-05-25       Impact factor: 5.858

Review 3.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 4.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 5.  Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.

Authors:  Sook Ryun Park; Alice Chen
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

6.  PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation.

Authors:  J-J Lee; B C Kim; M-J Park; Y-S Lee; Y-N Kim; B L Lee; J-S Lee
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

Review 7.  Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Authors:  Po Yee Yip
Journal:  Transl Lung Cancer Res       Date:  2015-04

8.  A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms.

Authors:  Rolando Perez-Lorenzo; Kamraan Z Gill; Che-Hung Shen; Feng X Zhao; Bin Zheng; Hans-Joachim Schulze; David N Silvers; Georg Brunner; Basil A Horst
Journal:  J Invest Dermatol       Date:  2013-11-28       Impact factor: 8.551

9.  Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.

Authors:  Charlotte E Edling; Federico Selvaggi; Ragheda Ghonaim; Tania Maffucci; Marco Falasca
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

10.  PTEN is a protein tyrosine phosphatase for IRS1.

Authors:  Yuji Shi; Junru Wang; Sarat Chandarlapaty; Justin Cross; Craig Thompson; Neal Rosen; Xuejun Jiang
Journal:  Nat Struct Mol Biol       Date:  2014-05-11       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.